Imperial College spinout MintNeuro has raised $5m (£3.8m), including participation from JSK Investments SICAV a.s.
The London-based spinout develops specialised chips for the next generation of neurotechnologies, enabling devices to interface with the brain and nervous system.
The company is currently focused primarily on medical applications, with the long-term ambition of becoming the standard chip platform for brain-computer interfaces.
MintNeuro will use the funding to bring its products to market, expand shipments of pre-production chips to partners and strengthen its presence, particularly in the US.
Petra Cihlářová, investment director of the venture capital sub-fund at JSK Investments SICAV a.s., said: “The main obstacle holding back neurotechnology today is not a lack of ideas, but hardware.
“MintNeuro is addressing this gap with a platform on which the entire industry can build. We were convinced to invest by its strong technology team, working chips and first long-term commercial contract.”
The round was led by Odyssey Ventures, with participation from JSK Investments, 33East and Alumni Ventures.
Existing investors, including Empirical Ventures and Jumpspace Ventures, also reinvested.
The round brings together DeepTech, MedTech and early-stage investors from Europe and the US.
Dorian Haci, co-founder and CEO of MintNeuro, said: “We are delighted to join the JSK portfolio and gain the backing of an investor with a strong network across Europe and the US, where we are now expanding our operations.
“With its healthcare connections and experience as both investors and entrepreneurs, our partnership with JSK will help us bring our chips closer to the developers and clinicians shaping the future of neural devices.
“We also greatly value the experience of JSK’s founders in building a business in international markets, which we can draw on during our next phase of commercial growth.”
This year, MintNeuro signed a multi-year agreement with Motif to supply chips for a minimally invasive neurostimulator initially targeting treatment-resistant depression.
A growing number of neural-device manufacturers and research teams are now testing or integrating MintNeuro’s technology.
Neural devices are opening up new possibilities for diagnosing and treating neurological and psychiatric conditions, from Parkinson’s disease and epilepsy to depression and hearing loss.
However, progress is being constrained by a shortage of chips designed to meet specific requirements for power consumption, size, safety and signal quality.
MintNeuro is therefore developing a modular semiconductor platform for sensing and processing neural signals and delivering targeted electrical stimulation.
This enables developers to build smaller, more energy-efficient devices and accelerate their progression from research to clinical use.
JSK Investments SICAV a.s. was established in 2025 and is led by Simona Kijonková
JSK Investments SICAV a.s. was established in 2025 as a self-managed investment fund led by Simona Kijonková.
It focuses primarily on direct equity investments in Czech and European companies, providing not only capital but also strategic support, entrepreneurial know-how and a hands-on approach.